Salt-form Patents Eligible for Listing

Summary#

The government published proposed changes to the Patented Medicines (Notice of Compliance) Regulations on April 24, 2021. The proposal would let makers of original drugs add patents that claim different salt, hydrate or solvate forms of a medicine to Health Canada's patent register, and give them 30 days to add such patents after the changes come into force. This is a proposal, not yet law.

What it does#

• Expands what counts as a patent "for the medicinal ingredient" so that patents claiming a different salt form (or the base form when the approved drug is a salt), or similar variations excluding only the appended salt/hydrate/solvate portions, can be listed on the patent register.
• Adds a short, temporary window that lets the original drug maker submit or resubmit eligible patents to the register within 30 days after these amendments come into force.
• Ties the timing so the changes are planned to come into force on the same day the Regulations Amending the Food and Drug Regulations (Improving Access to Generics) are registered (or on the day they are registered if that happens later).

Who's affected#

• Innovator pharmaceutical companies (the original drug makers) — they would be able to list more types of patents on Health Canada's register.
• Generic and biosimilar manufacturers — they may need to consider additional patents when preparing an abbreviated new drug submission.
• Health Canada — manages the patent register and the drug approval process.
• Patients and payers — indirectly affected because changes can influence when lower‑cost generics reach the market.
• It is unclear that small businesses face any new costs; the government says the change does not add administrative burdens.

Why it matters#

• The change is meant to keep the patent-protection rules in step with proposed updates to drug approval rules that make it clearer when generics can use different salt forms.
• Practically, it clarifies which patents can block or shape the timing of generic approvals. That can affect when cheaper generic drugs become available and how innovators and generics negotiate settlements or challenges.
• The government says the amendment restores balance between protecting drug patents and allowing timely generic entry, and that it should not add new costs to businesses.
• This is a proposed regulation with a public comment window of 30 days from publication on April 24, 2021.